An interventional study of PHIL® device in Arterio-venous Fistula and Intracranial Arteriovenous Malformations, sponsored by Alejandro Berenstein. Recruiting at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Alejandro Berenstein · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Arteriovenous Fistula with a site in United States — 6 open to participants now, 11 under way, none of them phase 3. Arteriovenous Fistula · United States.
Among the 60 studies in Arteriovenous Fistula with a site in United States, this one is the 37th largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2019, is one of 30 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 39th registered.
248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.
Browse Arteriovenous Fistula studies →6 of the 60 studies in Arteriovenous Fistula with a site in United States are open now. Recruiting first, the newest first:
Thomas Jefferson University · Sites in United States
Venova Medical · Sites in United States
Ages 18–80
Merit Medical Systems, Inc. · Sites in United States, Canada
Ages 18+
VenoStent · Sites in United States
Ages 18+
C. R. Bard · Sites in United States, Australia
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: Up to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 1
First in 1993; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 64 across 166 interventional studies indexed under Arteriovenous Fistula.
Median enrollment 65 across the 45 interventional studies, 60 across the 15 observational. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 60 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Alejandro Berenstein as lead sponsor.
Alejandro Berenstein has 1 study filed under Arteriovenous Fistula — fewer than ten, so there is no comparison to draw.
3 of the studies in Arteriovenous Fistula with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03506308C. R. BardPost Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae | 2027-04 |
| NCT04634916C. R. BardPost-market Surveillance Study of the BD® WavelinQ™ EndoAVF System | 2027-06 |
| NCT06001827VenoStentSAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 60 studies in Arteriovenous Fistula with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect information about how the PHIL® Embolic System works in the treatment of intracranial dural arteriovenous fistulas. Data collected in this study will be used to evaluate the safety and probable benefits in treating DAVFs.
The PHIL® Embolic System is a Humanitarian Use Device (HUD). The U.S. Food and Drug Administration (FDA) approved the use of the PHIL Embolic System as a HUD in June 2016.
Study design:The study is a prospective, single-center, single-arm, clinical study evaluating outcomes in pediatric subjects with intracranial dural arteriovenous fistulas treated with PHIL® device.
Study purpose: To evaluate the safety and probable benefit of MicroVention, Inc. PHIL® Liquid Embolic material in the treatment of intracranial dural arteriovenous fistulas, alone or as an adjunctive treatment for dAVFs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Using device
Device: PHIL® device
Using PHIL® device for treatment of intracranial dural arteriovenous fistulas
Proportion of participants with neurological death or major ipsilateral stroke
The proportion of subjects with neurological death or major ipsilateral stroke (defined as a major stroke within the vascular distribution of the vessel targeted for treatment) within 12 months following completion of treatment, reported as one composite data variable
Time frame: 12 months
Proportion of participants with angiographic occlusion
Proportion of subjects with Angiographic occlusion of the pre-specified target vessel intended for treatment at procedure following completion of treatment
Time frame: up to 12 months
Incidence of angiographic cure
Angiographic cure of the target dAVF, defined as complete obliteration of dAVF flow following final treatment.
Time frame: up to 12 months
Incidence of new-onset permanent morbidity
New-onset permanent morbidity up to 12 month follow-up
Time frame: up to 12 months
Incidence of new-onset Intracranial hemorrhage (ICH)
New-onset Intracranial hemorrhage (ICH) up to 12 month follow0up
Time frame: up to 12 months
Number of significant technical events
Clinically significant technical events during the PHIL embolization procedure(s) including but not limited to reflux of embolic material, migration of the embolic material, catheter entrapment or damage, and vessel dissection.
Time frame: up to 12 months
Incidence of device-related adverse events at procedure
Incidence of device-related adverse events at procedure at Day 1
Time frame: Day 1 during procedure
Incidence of device-related adverse events at 30 days
Incidence of device-related adverse events at 30 days.
Time frame: at 30 days
Incidence of device-related mortality
Device-related mortality at 30 days
Time frame: at 30 days
Incidence of procedure related adverse events
Procedure related adverse events including complications of arterial puncture, contrast-induced nephropathy, renal and anesthesia-related complications.
Time frame: up to 12 months
Incidence of cranial neuropathy
Incidence of cranial neuropathy up to 12 months follow-up
Time frame: up to 12 months
Pediatric NIH Stroke Scale (PedNIHSS)
PedNIHSS - 11 item instrument measuring levels of impairment on a scale of 0-42 with higher score demonstrating higher levels of impairment
Time frame: at 12 months
The Pediatric Stroke Outcome Measure (PSOM)
PSOM - measures stroke outcomes across 115 test items. On completion of the PSOM examination, the neurologist scores a Summary of Impressions containing 5 subscales: right sensorimotor, left sensorimotor (each with subcategories), language production, language comprehension, and cognitive/behavioral. Subscale scoring is 0 (no deficit), 0.5 (mild deficit, normal function), 1 (moderate deficit, decreased function), or 2 (severe deficit, missing function). The PSOM total score is the sum of the 5 subscale scores and ranges from 0 (no deficit) to 10 (maximum deficit).
Time frame: at 12 months
Number of procedures
Number of procedures required to treat the fistula at 3-6 month follow-up
Time frame: up to 6 months
Procedure time
Procedure time (defined as first to last fluoroscopic or digital subtraction angiographic acquisitions)
Time frame: average of 3-4 hours
Dosage of Radiation exposure
Time frame: average of 60 minutes
Radiation exposure time
Time frame: average of 60 minutes
Injected volume of PHIL
Time frame: at time of procedure, average of 3-4 hours
Started Apr 2019 (actual). Primary completion is estimated for Dec 2027, 104 months after the start.
Of 58 non-industry interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 43. This study's planned 104 months is above that.
Counting every sponsor, half of 84 studies reached it within 21 months; a quarter within 8 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.